DS
BTTX

David Shaw’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

David Shaw’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-31,848
Closed -$148K – 6079
2021
Q4 		$148K Buy
+31,848
New +$261K ﹤0.01% 4972

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

David Shaw's BTTX Position: Q1 2022 in Review

David Shaw sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2022, closing a stake of 31,848 shares — an estimated $148K sold.

David Shaw first reported a position in BTTX in Q4 2021 and held it in 1 quarter. The position peaked at $148K in Q4 2021. 14 funds tracked by Wall St. Rank hold BTTX as of Q1 2022.

  • David Shaw reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • David Shaw sold 31,848 Better Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $148K.
  • David Shaw first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • David Shaw's Better Therapeutics, Inc. Common Stock position peaked at $148K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.